Targeted agents and immunotherapies: optimizing outcomes in melanoma
The DOI matches its Crossref record; 166 of the 166 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 9×
“Dranoff, G. GM-CSF-based cancer vaccines.”
BackgroundInfluentialMutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationVogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citation
Cited by
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Long, G. V., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708539 · Cited by 1,490
Self-citationAnnual Report to the Nation on the Status of Cancer, part I: National cancer statistics
Cronin, K. A., Lake, A. J., Scott, S., Sherman, R. L., Noone, A., Howlader, N., Henley, S. J., Anderson, R. N., Firth, A. U., Ma, J., et al. (2018) · Cancer · doi:10.1002/cncr.31551 · Cited by 1,485
Current state of immunotherapy for glioblastoma
Lim, M., Xia, Y., Bettegowda, C., & Weller, M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0003-5 · Cited by 1,365
Tsoi, J., Robert, L., Paraiso, K., Galvan, C., Sheu, K. M., Lay, J., Wong, D. J. L., Atefi, M., Shirazi, R., Wang, X., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.017 · Cited by 938
“H stepwise stages and identify a heightened sensitivity to ferrop further define tumor differentiation as an important paramete component to add to standard of care therapeutics, namely en by synthetic-lethal induction of ferroptosis. survival (Luke et al., 2017).”
BackgroundSelf-citationAnnual report to the nation on the status of cancer, part I: National cancer statistics
Henley, S. J., Ward, E. M., Scott, S., Ma, J., Anderson, R. N., Firth, A. U., Thomas, C. C., Islami, F., Weir, H. K., Lewis, D. R., et al. (2020) · Cancer · doi:10.1002/cncr.32802 · Cited by 853
Cutaneous melanoma: From pathogenesis to therapy (Review)
Leonardi, G., Falzone, L., Salemi, R., Zangh�, A., Spandidos, D., Mccubrey, J., Candido, S., & Libra, M. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4287 · Cited by 588
Therapy with oncolytic viruses: progress and challenges
Shalhout, S. Z., Miller, D. M., Emerick, K. S., & Kaufman, H. L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00719-w · Cited by 584
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations
Dankner, M., Rose, A. A. N., Rajkumar, S., Siegel, P. M., & Watson, I. R. (2018) · Oncogene · doi:10.1038/s41388-018-0171-x · Cited by 550
Luke, J. J., Rutkowski, P., Queirolo, P., Del Vecchio, M., Mackiewicz, J., Chiarion-Sileni, V., de la Cruz Merino, L., Khattak, M. A., Schadendorf, D., Long, G. V., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00562-1 · Cited by 499
Self-citationExosome-based immunotherapy: a promising approach for cancer treatment
Xu, Z., Zeng, S., Gong, Z., & Yan, Y. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01278-3 · Cited by 482
Cheng, L., Lopez-Beltran, A., Massari, F., MacLennan, G. T., & Montironi, R. (2018) · Modern Pathology · doi:10.1038/modpathol.2017.104 · Cited by 407
Adoptive cellular therapies: the current landscape
Rohaan, M. W., Wilgenhof, S., & Haanen, J. B. A. G. (2019) · Virchows Archiv · doi:10.1007/s00428-018-2484-0 · Cited by 398
Targeting FAK in anticancer combination therapies
Dawson, J. C., Serrels, A., Stupack, D. G., Schlaepfer, D. D., & Frame, M. C. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00340-6 · Cited by 384
Signal pathways of melanoma and targeted therapy
Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 379
Phenotype plasticity as enabler of melanoma progression and therapy resistance
Arozarena, I., & Wellbrock, C. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0154-4 · Cited by 381
Tang, X., Yang, T., Yu, D., Xiong, H., & Zhang, S. (2024) · Environment International · doi:10.1016/j.envint.2024.108535 · Cited by 371
Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead
Oiseth, S. J., & Aziz, M. S. (2017) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2017.41 · Cited by 369
Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment
Marzagalli, M., Ebelt, N. D., & Manuel, E. R. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.002 · Cited by 345
Treatment of Advanced Melanoma in 2020 and Beyond
Jenkins, R. W., & Fisher, D. E. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.03.943 · Cited by 339
Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities
Rambow, F., Marine, J.-C., & Goding, C. R. (2019) · Genes & Development · doi:10.1101/gad.329771.119 · Cited by 325
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Ascierto, P. A., Ferrucci, P. F., Fisher, R., Del Vecchio, M., Atkinson, V., Schmidt, H., Schachter, J., Queirolo, P., Long, G. V., Di Giacomo, A. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0448-9 · Cited by 324
Self-citationWard, E. M., Sherman, R. L., Henley, S. J., Jemal, A., Siegel, D. A., Feuer, E. J., Firth, A. U., Kohler, B. A., Scott, S., Ma, J., et al. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz106 · Cited by 323
Targeting ERK1/2 protein-serine/threonine kinases in human cancers
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.039 · Cited by 308
Rodriguez-Meira, A., Buck, G., Clark, S.-A., Povinelli, B. J., Alcolea, V., Louka, E., McGowan, S., Hamblin, A., Sousos, N., Barkas, N., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.01.009 · Cited by 305
Molecular and nanoengineering approaches towards activatable cancer immunotherapy
Zhang, C., & Pu, K. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00773c · Cited by 302
Cursons, J., Souza-Fonseca-Guimaraes, F., Foroutan, M., Anderson, A., Hollande, F., Hediyeh-Zadeh, S., Behren, A., Huntington, N. D., & Davis, M. J. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0500 · Cited by 296
Survival of patients with advanced metastatic melanoma: the impact of novel therapies–update 2017
Ugurel, S., Röhmel, J., Ascierto, P. A., Flaherty, K. T., Grob, J. J., Hauschild, A., Larkin, J., Long, G. V., Lorigan, P., McArthur, G. A., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.028 · Cited by 287
Self-citationMany ways to resistance: How melanoma cells evade targeted therapies
Kozar, I., Margue, C., Rothengatter, S., Haan, C., & Kreis, S. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.02.002 · Cited by 270
Dafni, U., Michielin, O., Lluesma, S. M., Tsourti, Z., Polydoropoulou, V, Karlis, D., Besser, M. J., Haanen, J., Svane, I. M., Ohashi, P. S., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz398 · Cited by 263
Cheng, N., Watkins-Schulz, R., Junkins, R. D., David, C. N., Johnson, B. M., Montgomery, S. A., Peine, K. J., Darr, D. B., Yuan, H., McKinnon, K. P., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120638 · Cited by 260
Simpson, R. C., Shanahan, E. R., Batten, M., Reijers, I. L. M., Read, M., Silva, I. P., Versluis, J. M., Ribeiro, R., Angelatos, A. S., Tan, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01965-2 · Cited by 256
Self-citationNiraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
Wang, Z., Sun, K., Xiao, Y., Feng, B., Mikule, K., Ma, X., Feng, N., Vellano, C. P., Federico, L., Marszalek, J. R., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-38534-6 · Cited by 253
Mechanisms of UV-induced mutations and skin cancer
Pfeifer, G. P. (2020) · Genome Instability & Disease · doi:10.1007/s42764-020-00009-8 · Cited by 237
Haas, L., Elewaut, A., Gerard, C. L., Umkehrer, C., Leiendecker, L., Pedersen, M., Krecioch, I., Hoffmann, D., Novatchkova, M., Kuttke, M., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00221-9 · Cited by 223
Self-citationAdoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option
Rohaan, M. W., van den Berg, J. H., Kvistborg, P., & Haanen, J. B. A. G. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0391-1 · Cited by 196
“Less than a decade ago, the treatment options were very limited for patients with advanced stage disease and the 5-year overall survival (OS) was only 9–28% [2, 3].”
BackgroundCutaneous Malignant Melanoma: A Review of Early Diagnosis and Management
Naik, P. P. (2021) · World Journal of Oncology · doi:10.14740/wjon1349 · Cited by 177
VanderWalde, A., Bellasea, S. L., Kendra, K. L., Khushalani, N. I., Campbell, K. M., Scumpia, P. O., Kuklinski, L. F., Collichio, F., Sosman, J. A., Ikeguchi, A., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02498-y · Cited by 176
Self-citationTowards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
Simpson, R. C., Shanahan, E. R., Scolyer, R. A., & Long, G. V. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00803-9 · Cited by 153
Self-citationTrial Watch: Immunomodulatory monoclonal antibodies for oncological indications
Buqué, A., Bloy, N., Aranda, F., Castoldi, F., Eggermont, A., Cremer, I., Fridman, W. H., Fucikova, J., Galon, J., Marabelle, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008814 · Cited by 136
Oxidative stress and antioxidants in the pathophysiology of malignant melanoma
Obrador, E., Liu-Smith, F., Dellinger, R. W., Salvador, R., Meyskens, F. L., & Estrela, J. M. (2019) · Biological Chemistry · doi:10.1515/hsz-2018-0327 · Cited by 119
Circulating tumour DNA (CtDNA) as a liquid biopsy for melanoma
Calapre, L., Warburton, L., Millward, M., Ziman, M., & Gray, E. S. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.030 · Cited by 118
Maertens, O., Kuzmickas, R., Manchester, H. E., Emerson, C. E., Gavin, A. G., Guild, C. J., Wong, T. C., De Raedt, T., Bowman-Colin, C., Hatchi, E., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0879 · Cited by 95
“Combined BRAF and MEK inhibitors (dabrafenib/trametinib) were used to suppress the MAPK pathway in BRAF-mutant cells, as this represents the standard of care (2), whereas trametinib alone was used in NRAS- and NF1mutant cell lines.”
BackgroundMethodSelf-citationWang, X., Barrera, C., Bera, K., Viswanathan, V. S., Azarianpour-Esfahani, S., Koyuncu, C., Velu, P., Feldman, M. D., Yang, M., Fu, P., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn3966 · Cited by 89
The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer
Mauri, G., Bonazzina, E., Amatu, A., Tosi, F., Bencardino, K., Gori, V., Massihnia, D., Cipani, T., Spina, F., Ghezzi, S., et al. (2021) · Cancers · doi:10.3390/cancers13010137 · Cited by 73
“Similarly to early trials of BRAF targeting in mCRC, this strategy has been derived from melanoma [70,71].”
Taking advantage of drug resistance, a new approach in the war on cancer
Wang, L., & Bernards, R. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0647-7 · Cited by 53
Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma
Lucas, M. W., Versluis, J. M., Rozeman, E. A., & Blank, C. U. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00760-3 · Cited by 50
Rawat, V., Malvi, P., Della Manna, D., Yang, E. S., Bugide, S., Zhang, X., Gupta, R., & Wajapeyee, N. (2021) · Oncogene · doi:10.1038/s41388-021-01683-y · Cited by 43
Macandog, A. D. G., Catozzi, C., Capone, M., Nabinejad, A., Nanaware, P. P., Liu, S., Vinjamuri, S., Stunnenberg, J. A., Galiè, S., Jodice, M. G., et al. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.10.006 · Cited by 40
“The introduction of immune checkpoint inhibitor (ICI) therapy in the last decade set a precedent for melanoma treatment, significantly improving patient outcome 1,2 in an otherwise therapy-resistant cancer type.”
Biological Basis for Novel Mesothelioma Therapies
Obacz, J., Yung, H., Shamseddin, M., Linnane, E., Liu, X., Azad, A. A., Rassl, D. M., Fairen-Jimenez, D., Rintoul, R. C., Nikolić, M. Z., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01462-2 · Cited by 31
Nti, A. A., Serrano, L. W., Sandhu, H. S., Uyhazi, K. E., Edelstein, I. D., Zhou, E. J., Bowman, S., Song, D., Gangadhar, T. C., Schuchter, L. M., et al. (2019) · Retina · doi:10.1097/iae.0000000000002027 · Cited by 31
Drug repurposing: An emerging strategy in alleviating skin cancer
Kumbhar, P., Kole, K., Yadav, T., Bhavar, A., Waghmare, P., Bhokare, R., Manjappa, A., Jha, N. K., Chellappan, D. K., Shinde, S., et al. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175031 · Cited by 28
Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo
Hartsough, E. J., Kugel, C. H., Vido, M. J., Berger, A. C., Purwin, T. J., Goldberg, A., Davies, M. A., Schiewer, M. J., Knudsen, K. E., Bollag, G., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0705 · Cited by 27
“Furthermore, immunotherapy approaches are generally not suitable for patients with bulky disease that require rapid intervention (16), and an initial clinical trial combining vemurafenib with ipilimumab (a CTLA-4–targeting agent) resulted in significant hepatotoxicity (17).”
Targeting GPCRs and Their Signaling as a Therapeutic Option in Melanoma
Raymond, J. H., Aktary, Z., Larue, L., & Delmas, V. (2022) · Cancers · doi:10.3390/cancers14030706 · Cited by 20
Blazek, K., Furestad, E., Ryan, D., Damian, D., Fernandez-Penas, P., & Tong, S. (2022) · Cancer Epidemiology · doi:10.1016/j.canep.2022.102263 · Cited by 18
Machado, M. A. D. Á., de Moura, C. S., Chan, K., Curtis, J. R., Hudson, M., Abrahamowicz, M., Jamal, R., Pilote, L., & Bernatsky, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-71788-z · Cited by 14
Martinović, K. M., Vuletić, A., Miletić, N. T., Nedeljković, M., Matković, S., & Jurišić, V. (2025) · Clinical Immunology · doi:10.1016/j.clim.2025.110557 · Cited by 5
Metadata
- Authors
- Luke, J. J., Flaherty, K. T., Ribas, A., & Long, G. V.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2017-04-04
- Volume
- 14
- Issue
- 8
- Pages
- 463-482
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2605233023
- Cited by
- 1,254
- References
- 166
- FWCI
- 9.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.